Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M (2016) Activating and tranquilizing effects of First-Time treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth. J Child Adolesc Psychopharmacol 26(5):458–470

CAS  PubMed  PubMed Central  Google Scholar 

Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H, Theisen FM (2008) Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 30(4):462–466

CAS  PubMed  Google Scholar 

Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss H-J, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37(6):243–265

CAS  PubMed  Google Scholar 

Carbon M, Kapoor S, Sheridan E, Al-Jadiri A, Azzo S, Sarkaria T, Kane JM, Saito E, Correll CU (2015) Neuromotor adverse effects in 342 Youth during 12 weeks of naturalistic treatment with 5 second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry 54(9):718–727e3

PubMed  PubMed Central  Google Scholar 

Conley RR, Kelly DL (2007) Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 40(1):77–97

PubMed  Google Scholar 

Conn RL, Kearney O, Tully MP, Shields MD, Dornan T (2019) What causes prescribing errors in children? Scoping review. BMJ open 9(8):e028680

PubMed  PubMed Central  Google Scholar 

Constantine RJ, Boaz T, Tandon R (2010) Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 32(5):949–959

PubMed  Google Scholar 

Correll CU, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45(7):771–791

PubMed  Google Scholar 

Correll CU, Kohegyi E, Zhao C, Baker RA, McQuade R, Salzman PM, Sanchez R, Nyilas M, Carson W (2017) Oral aripiprazole as maintenance treatment in adolescent Schizophrenia: results from a 52-Week, Randomized, Placebo-Controlled Withdrawal Study. J Am Acad Child Adolesc Psychiatry 56(9):784–792

PubMed  Google Scholar 

Egberts K, Karwautz A, Plener PL, Mehler-Wex C, Kölch M, Dang S-Y, Taurines R, Romanos M, Gerlach M (2015) Pharmakovigilanz in Der kinder- und jugendpsychiatrie (Pharmacovigilance in child and adolescent psychiatry). Z fur Kinder- und Jugendpsychiatrie Und Psychother 43(1):21–28

Google Scholar 

Egberts K, Reuter-Dang S, Fekete S, Kulpok C, Mehler-Wex C, Wewetzer C, Karwautz A, Mitterer M, Holtkamp K, Boege I, Burger R, Romanos M, Gerlach M, Taurines R (2020) Therapeutic drug monitoring of children and adolescents treated with aripiprazole: observational results from routine patient care. J Neural Transmission (Vienna Austria: 1996) 127(12):1663–1674

CAS  Google Scholar 

Egberts K, Fekete S, Häge A, Hiemke C, Scherf-Clavel M, Taurines R, Unterecker S, Gerlach M, Romanos M (2021) Therapeutisches Drug Monitoring Zur Optimierung Der Psychopharmakotherapie Von Kindern Und Jugendlichen (therapeutic drug monitoring to optimize psychopharmacotherapy in children and adolescents - update and guidelines for practice). Z fur Kinder- und Jugendpsychiatrie Und Psychother 50(2):133–152

Google Scholar 

Egberts K, Gerlach M, Correll CU, Plener PL, Malzahn U, Heuschmann P, Unterecker S, Scherf-Clavel M, Rock H, Antony G, Briegel W, Fleischhaker C, Häge A, Hellenschmidt T, Imgart H, Kaess M, Karwautz A, Kölch M, Reitzle K, Renner T, Reuter-Dang S-Y, Rexroth C, Schulte-Körne G, Theisen FM, Walitza S, Wewetzer C, Fekete S, Taurines R, Romanos M (2022) Serious adverse drug reactions in children and adolescents treated On- and off-label with antidepressants and antipsychotics in clinical practice. Pharmacopsychiatry 55(5):255–265

CAS  PubMed  PubMed Central  Google Scholar 

Findling RL, Kauffman RE, Sallee FR, Carson WH, Nyilas M, Mallikaarjun S, Shoaf SE, Forbes RA, Boulton DW, Pikalov A (2008) Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 28(4):441–446

CAS  PubMed  Google Scholar 

Findling RL, Correll CU, Nyilas M, Forbes RA, McQuade RD, Jin N, Ivanova S, Mankoski R, Carson WH, Carlson GA (2013) Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord 15(2):138–149

CAS  PubMed  Google Scholar 

Gerlach M, Warnke A, Greenhill L (eds) (2014) Psychiatric drugs in children and adolescents. Springer Vienna, Vienna

Google Scholar 

Gerlach M, Egberts K, Dang S-Y, Plener PL, Taurines R, Mehler-Wex C, Romanos M (2016) Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Exp Opin Drug Saf 15(11):1477–1482

CAS  Google Scholar 

Guy W (1976) Clinical global impressions. ECDEU Assessment Manual for psychopharmacology – revised. US Department of Health, Education, and Welfare; Psychopharmacology Research Branch. Division of Extramural Research Programs, pp 218–222

Hart XM, Gründer G, Zurek G, Sputtek A (2020) P6.6 Comparative study of suggested reference values and observed distributions in daily routine of a medical laboratory. Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP 2020

Hart XM, Eichentopf L, Lense X, Riemer T, Wesner K, Hiemke C, Gründer G (2021) Therapeutic reference ranges for psychotropic drugs: a protocol for systematic reviews. Front Psychiatry 12:787043

PubMed  PubMed Central  Google Scholar 

Hendset M, Molden E, Knape M, Hermann M (2014) Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit 36(1):80–85

CAS  PubMed  Google Scholar 

Hiemke C (2019) Concentration-Effect relationships of psychoactive drugs and the Problem to calculate therapeutic reference ranges. Ther Drug Monit 41(2):174–179

PubMed  Google Scholar 

Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud SE, Kirchherr H, Laux G, Lutz UC, Messer T, Müller JM, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP Consensus guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44(6):195–235

PubMed  Google Scholar 

Hiemke C, Bergemann N, Clement H-W, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud SE, Laux G, Messer T, Mössner R, Müller JM, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl J, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51(1–02):9–62

CAS  PubMed  Google Scholar 

Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441(3):137–140

CAS  PubMed  Google Scholar 

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito G, Zimbroff DL, Ali M (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63(9):763–771

CAS  PubMed  Google Scholar 

Kapfhammer H-P, Karwautz A, Sachs G (2010) Arzneimittelprofil Psychatrie. Aripiprazol. Medizin Median Austria

Keck PE, Marcus RN, Tourkodimitris S, Ali M, Liebeskind A, Saha AR, Ingenito G (2003) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160(9):1651–1658

PubMed  Google Scholar 

Kim J-R, Seo H-B, Cho J-Y, Kang D-H, Kim YK, Bahk W-M, Yu K-S, Shin S-G, Kwon JS, Jang I-J (2008) Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 66(6):802–810

CAS  PubMed  PubMed Central  Google Scholar 

Kirschbaum KM, Müller JM, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C (2008) Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry: Official J World Federation Soc Biol Psychiatry 9(3):212–218

Google Scholar 

Kloosterboer SM, Vierhout D, Stojanova J, Egberts K, Gerlach M, Dieleman GC, Hillegers MHJ, Passe KM, van Gelder T, Dierckx B, Koch BCP (2020) Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Exp Opin Drug Saf 19(7):873–890

CAS  Google Scholar 

Kloosterboer SM, de Winter BCM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, van Daalen E, Ester WA, Rieken R, Dieleman GC, van Altena D, Bartelds B, van Schaik RHN, Nasserinejad K, Hillegers MHJ, van Gelder T, Dierckx B, Koch BCP (2021) Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol 87(3):1069–1081

CAS  PubMed  Google Scholar 

Koch MT, Carlson HE, Kazimi MM, Correll CU (2023) Antipsychotic-related prolactin levels and sexual dysfunction in mentally Ill Youth: a 3-Month Cohort Study. J Am Acad Child Adolesc Psychiatry 62(9):1021–1050

PubMed  PubMed Central  Google Scholar 

Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O (2012) Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22(2):157–165

CAS  PubMed  Google Scholar 

Lai C-H, Wu Y-T, Chen C-Y, Hou Y-C (2016) Gray Matter increases in fronto-parietal regions of depression patients with aripiprazole monotherapy: an exploratory study. Medicine 95(34):e4654

CAS  PubMed  PubMed Central  Google Scholar 

Lin S-K, Chen C-K, Liu Y-L (2011) Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol 31(6):758–762

CAS  PubMed  Google Scholar 

March J, Karayal O, Chrisman A (2007) CAPTN: The pediatric adverse event rating scale. The Scientific Proceedings of the 2007 Annual Meeting of the American Academy of Child and Adolescent Psychiatry: 23–28

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28(2):156–165

CAS  PubMed  Google Scholar 

Mizutani T (2003) PM frequencies of major CYPs in asians and caucasians. Drug Metab Rev 35(2–3):99–106

CAS  PubMed